Today: 18 January 2026
Subscribe
Browse Category

Biotech News 9 December 2025 - 20 December 2025

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for…
20 December 2025
····
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era blockbuster). The stock last traded around $33.80, up roughly 9% from the prior close, with a market cap near $13…
20 December 2025
····
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics, Inc. (NASDAQ: FOLD) ended Friday’s session (December 19, 2025) in a very different place than it started: the stock re-priced into “deal mode” after BioMarin Pharmaceutical (NASDAQ: BMRN) announced a definitive agreement to acquire Amicus in an all-cash transaction valued at roughly $4.8 billion. BioMarin Investors With U.S. markets closed on the weekend, the “tomorrow open” investors are…
20 December 2025
····
Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Updated: Tuesday, December 16, 2025 | Early afternoon ET (U.S. stock market) Biotechnology stocks are delivering a classic split-screen session in the U.S. market today: biotech ETFs are slipping, but a handful of single-name biotech movers are swinging sharply on FDA updates, clinical data, and year-end dealmaking. By early afternoon in New York (based on the latest available quotes at the time of…
16 December 2025
···
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics (NASDAQ: NKTR) is in classic “biotech catalyst mode” on December 16, 2025—the kind of day when a single dataset can rewrite a stock chart in minutes. Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational…
16 December 2025
····
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets,…
12 December 2025
····
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

December 11, 2025 – Roivant Sciences Ltd. (Nasdaq: ROIV) has just given Wall Street a dense dose of biotech optimism. Here’s what today’s Investor Day and the latest data mean for the stock. ROIV stock today: rally near 52‑week highs Roivant shares traded around the low‑$20s on December 11, with intraday prices near $21.5 according to real‑time market data. That…
11 December 2025
····
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors

Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors

Vor Biopharma Inc. (NASDAQ: VOR) has exploded back onto traders’ screens. On December 9, 2025, the small-cap biotech surged roughly 31%, closing around $10.95 versus $8.36 the prior session, on volume tens of millions of shares—far above its recent daily average. StockAnalysis The move followed new bullish coverage from JPMorgan, fresh clinical data around Vor’s lead drug telitacicept, and a…
9 December 2025
···
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)

Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)

Biotech investors faced a dense catalyst calendar on Tuesday, December 9, 2025, as new U.S. Food and Drug Administration (FDA) signals on cell and gene therapy, fresh designations in hematologic cancers and high‑impact clinical data from the American Society of Hematology (ASH) meeting collided with a wave of secondary offerings. Despite a string of double‑digit movers, the sector finished in…
9 December 2025
·
Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

As of December 9, 2025, shares of Legend Biotech Corporation (NASDAQ: LEGN) are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls and technical signals that are driving sentiment around Legend Biotech stock today. Where Legend Biotech Stock Trades Now Legend Biotech’s…
9 December 2025
···
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune, Inc. (NASDAQ: ALT) has become a tightly wound biotech story heading into year‑end 2025. The small‑cap developer of liver and metabolic drugs is changing its CEO just weeks before a pivotal 48‑week readout in its lead MASH trial, while Wall Street models still point to triple‑digit upside from today’s share price. As of mid‑day on December 9, 2025, Altimmune…
9 December 2025
····
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading. Exicure Below is a comprehensive…
9 December 2025
····
1 2 3 4 5 6 … 12

Stock Market Today

  • IREN shares jump 11% on Friday as MLK Day market break looms; Microsoft AI deal, crypto outlook in focus
    January 18, 2026, 1:38 PM EST. IREN Limited shares jumped 11.4% to $57.82 on Friday, with a 0.8% gain in after-hours trade. U.S. markets were closed Monday for MLK Day; trading resumes Tuesday. The move followed an upgrade by H.C. Wainwright & Co. from sell to buy on Jan. 13 and a Microsoft AI cloud deal valued around $9.7 billion that gives access to Nvidia GPUs via Dell for AI work. IREN runs renewable-powered data centers and mines crypto while offering AI cloud services; Reuters notes it uses about 1,896 Nvidia GPUs. Friday's action was volatile: intraday swing from $51.85 to $58.74 on about 54 million shares. Peers Riot Platforms and Marathon Digital rose on the same theme, including AMD data-center leases. Risks include large capex, higher power costs, crypto-price moves, and potential delivery delays. Earnings due Feb. 11-12 per MarketBeat.
Go toTop